ARCHIVES

PV-10 Produces 51 Percent Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

September 27, 2002

July issue of Business & Regulatory report (8 additional pages) included.

July 30, 2004

AACI Asks NCI to Reconsider Dropping CCPDS Support, Find New Mechanism to Fund Center Outreach Effort

July 9, 1982

Advisers Discuss What To Do About Physician-Scientists

May 1, 1992

Newell Describes Progress To House, Senate Subcommittees

March 25, 1977

Duke Retraction May Alter IOM Investigation; Review Panel Membership Announced

November 5, 2010